Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: KS24.22 cells
Sponsor: University Hospital Tuebingen
Collaborators: Paul Ehrlich Institute, Langen, Germany